Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.
Hangzhou Tigermed Consulting Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to review and approve the company’s unaudited interim results for the first half of 2025. The meeting will also consider the declaration and payment of an interim dividend, which could impact the company’s financial positioning and shareholder returns.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in China, operating within the consulting industry. It focuses on providing consulting services, likely in the healthcare or pharmaceutical sectors, given its name and typical industry associations.
YTD Price Performance: 91.14%
Average Trading Volume: 5,285,100
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.02B
See more data about 3347 stock on TipRanks’ Stock Analysis page.